Levels of vaccination coverage among HIV-exposed children in China: a retrospective study

Table 4 Vaccination up to date status in the study population

Vaccine	Total N	UTD n (%)	PHIV		HEU		Unknown
			n (%)	OR (95% CI)	n (%)	OR (95% CI)	n (%)	OR (95% CI)
			n (%)	P-value^a	n (%)	P-value^a	n (%)	P-value^a
BCG	9883	5041 (51.0)	82 (27.0)	1.00 –	4 900 (52.6)	3.00 (2.32‒3.88) < 0.001	59 (22.6)	0.79 (0.54‒1.16) 0.232
HepB3	9902	7928 (80.1)	155 (50.8)	1.00 –	7 720 (82.8)	4.65 (3.69‒5.85) < 0.001	53 (19.7)	0.24 (0.16‒0.35) < 0.001
Polio3	9827	4848 (49.3)	58 (19.1)	1.00 –	4 758 (51.3)	4.45 (3.33‒5.94) < 0.001	32 (12.7)	0.62 (0.39‒0.99) 0.044
MCV	9822	4582 (46.6)	52 (17.1)	1.00 –	4 504 (48.6)	4.58 (3.39‒6.20) < 0.001	26 (10.3)	0.56 (0.34‒0.92) 0.023
DTP3	9821	5257 (53.5)	77 (25.4)	1.00 –	5 144 (55.5)	3.66 (2.82‒4.76) < 0.001	36 (14.3)	0.49 (0.32‒0.76) 0.001

BCG Bacillus-Calmette-Guérin, CI confidence interval, DTP diphtheria-tetanus-pertussis-containing, HEU HIV-exposed uninfected, HIV human immunodeficiency virus, HepB hepatitis B, MCV measles-containing vaccine, N number of children, n number of children with the characteristic, OR odds ratio, PHIV perinatally acquired HIV, children perinatally infected with HIV from mothers, UTD up to date, children were classified as up to date if they had received the recommended dose of vaccines before 12 months of age. – means not applicable
^aUnivariate logistic regression

ISSN: 2049-9957